PlainRecalls
FDA Drug Moderate Class II Ongoing

Duloxetine Delayed-Release Capsules, USP, 60mg, 1,000-count bottles, Rx Only, Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Distributed by: Breckenridge Pharmaceuticals, Inc., Berkeley Heights, NJ 07922. NDC 51991-748-10.

Reported: August 13, 2025 Initiated: July 15, 2025 #D-0552-2025

Product Description

Duloxetine Delayed-Release Capsules, USP, 60mg, 1,000-count bottles, Rx Only, Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Distributed by: Breckenridge Pharmaceuticals, Inc., Berkeley Heights, NJ 07922. NDC 51991-748-10.

Reason for Recall

CGMP Deviations: Presence of N-nitroso-duloxetine impurity above safety assessment limit

Details

Units Affected
1,829 60-count bottles
Distribution
U.S Nationwide
Location
Berkeley Heights, NJ

Frequently Asked Questions

What product was recalled?
Duloxetine Delayed-Release Capsules, USP, 60mg, 1,000-count bottles, Rx Only, Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Distributed by: Breckenridge Pharmaceuticals, Inc., Berkeley Heights, NJ 07922. NDC 51991-748-10.. Recalled by Breckenridge Pharmaceutical, Inc.. Units affected: 1,829 60-count bottles.
Why was this product recalled?
CGMP Deviations: Presence of N-nitroso-duloxetine impurity above safety assessment limit
Which agency issued this recall?
This recall was issued by the FDA Drug on August 13, 2025. Severity: Moderate. Recall number: D-0552-2025.